Table 1.

Overview of RCTs assessing therapies explored in RECOVERY (based on 4,673 RCTs registered as of February 28, 2022).

Intervention	RECOVERY results release date	N of trials (% of all trials)	N of all trials registered Before/After RECOVERY results released	N of trials with a German part Before/after RECOVERY	Planned sample size all trials§ •total •per trial (median, IQR)	Planned sample size with a Geman part •total •per trial (median, IQR)
Hydroxychloroquine	5 Jun 2020	340 (7.3%)	259/80*	6/0	•483,019 •131 [60; 450]	•111, 808; •220 [17; 11,557]
Dexamethasone	16 Jun 2020	86 (1.8%)	20/66	none	•25,631 •120 [60; 302]	-
Lopinavir-Ritonavir	29 Jun 2020	105 (2.2%)	81/24	1/0	•227,303 •108 [60; 435]	•11,557 •11,557
Azithromycin	14 Dec 2020	100 (2.1%)	90/10	none	•81,524 •120 [60; 267]	-
Convalescent plasma	15 Jan 2021	100 (2.1%)	92/8	6/0	•83,006 •110 [60; 305]	•13,343; •257 [134; 906]
Tocilizumab	11 Feb 2021	75 (1.6%)	64/11	3/0	•95,518 •150 [61; 290]	•12,209; •452 [326; 6,004]
Colchicine	5 May 2021	62 (1.3%)	44/18	none	•95,317 •124 [79; 309]	•-
Aspirin	8 Jun 2021	17 (0.4%)	16/1	1/0	•68,225 •128 [61; 1,000]	•11,557 •11,557
Regeneron's monoclonal antibody combination	16 Jun 2021	11 (0.2%)	5/6	none	•29,725 •1,359 [348; 3,600]	-
Baricitinib	3 Mar 2022	21 (0.4%)	21/0	2/0	•68,617 •1,010 [165; 1,500]	•3,425; •1,712 [1,619; 1,809]

Abbreviations: CI: Confidence Intervals; IQR: Interquartile range.

27 RCTs had missing information on the intervention being assessed.

^*Missing registration date for 1 RCT for hydroxychloroquine.

^§Missing planned sample size for 60 RCTs for hydroxychloroquine; 5 for vaccine; 4 for lopinavir-ritonavir; 11 for azithromycin; 2 for tocilizumab; 1 for dexamethasone; 2 aspirin; 2 colchicine; 2 for convalescent plasma; and 4 for chloroquine.